Morning Joe
On August 7, MBI gained international recognition when it was featured on MSNBC — one of the leading news networks in the United States — during Morning Joe, a national broadcast. Our founder, Fernando Goldsztein, was invited to speak about the initiative’s global impact and advances in pediatric brain tumor research. He highlighted how the […]
MBI’s Voice in The Washington Post
On June 7, we had the honor of seeing a letter from our founder published in The Washington Post, one of the most respected newspapers in the United States. The letter, featured in the Letters to the Editor section, addresses the challenges faced by children with brain tumors, especially medulloblastoma, and calls out the lack […]
Lemonade for a Cure
This is the third season that 7-year-old Kennedy has dedicated her time to raising funds for pediatric cancer. With the support of her family and community, she has collected donations that, in 2025, are being directed to MBI. Kennedy’s mother, Kelly, shared that her daughter has many supporters and set up her lemonade stand several […]
MBI at the CAC2 2025 Annual Summit
In June, we participated for the first time in the CAC2 2025 Annual Summit, held at Children’s National Hospital in Washington, DC. MBI joined as a sponsor, and Fernando Goldsztein was one of the event’s speakers. Our founder led a packed session with leaders from other organizations dedicated to childhood cancer. He spoke about the […]
MBI Stands out at YPO Event with high-impact presentation
We recently participated in the YPO Impact Week in São Paulo, Brazil, with the panel “Turning Pain into Action: The Power of a Cause.” Our founder, Fernando Goldsztein, spoke about the future of research and shared how his personal experience with his son’s diagnosis led to the creation of MBI – now an international reference […]
MBI and its founder in the media spotlight
In the first months of 2025, MBI’s founder, Fernando Goldsztein, was featured in four outstanding Brazilian podcasts. Each conversation brought a unique perspective—some focused on leadership and the creation of an innovative operating model, while others highlighted family life or the scientific breakthroughs driving the Medulloblastoma Initiative forward. Every interview carried its own tone and […]
Clinical trial with innovative therapy begins treating children with cancer
In May 2025, the first children with medulloblastoma received the experimental treatment in the MATCHPOINT study, representing an unprecedented breakthrough funded by MBI. While these initial patients begin therapy, new pediatric and young adult participants with recurrent or refractory medulloblastoma continue to be recruited for the clinical trial in the U.S. FDA-approved in 2024, the […]
MBI in the spotlight: a feature by MIT News
“The MBI blueprint for funding cures for rare diseases is replicable and likely to disrupt the standard way health care research is funded and carried out by radically shortening the timeline.” MBI has been highlighted by one of the most prestigious institutions in the world, MIT – Massachusetts Institute of Technology. An article showcasing our […]
MBI takes medulloblastoma fight to national spotlight on Fox 5
During Brain Cancer Awareness Month, Fernando Goldsztein, MBI’s founder, and Dr. Roger J. Packer, scientific leader, appeared live on FOX 5 DC to share details about our groundbreaking work. FOX 5, a regional affiliate of Fox Broadcasting Company, reaches over 200 million viewers daily across the U.S. Watch the full segment here. While awareness opens […]
MBI founder discusses scientific progress on the Society for Neuro-Oncology Latin America podcast
A conversation about neuro-oncology—and about life. That was the focus of the latest episode of the SNOLA (Society for Neuro-Oncology Latin America) podcast, featuring MBI founder Fernando Goldsztein. Fernando joined two leading experts from SNOLA’s board: Dr. Caroline Chaul Barbosa, Neuro-oncologist at Hospital Sírio-Libanês, and Dr. Marcos Vinicius Calfat Maldaun, Neurosurgeon, Director of the Neuro-oncology […]